Oncostatin M Receptor in Pancreatic Cancer
Official title: Oncostatin M Receptor in Pancreatic Adenocarcinoma
Funded at Portland VA Medical Center · NIH-11402385 · Data updated 2026-11-12
Aims to understand how a molecule called Oncostatin M and its receptor affect pancreatic cancer to find new ways to help patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Portland VA Medical Center NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2027 |
| NIH project number | 5I01BX006305-03 |
| Project ID | NIH-11402385 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with pancreatic ductal adenocarcinoma or related tumor tissues may be relevant for translational studies and future trials.
✕Less likely to help
Patients without PDAC or without access to future trials stemming from this research may not benefit directly.
What this research studies
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with limited treatment options. This project looks at how Oncostatin M (OSM) and its receptor OSMR influence the tumor environment, cancer cell behavior, and signaling pathways that drive growth and resistance. By studying PDAC cells and tumor samples, researchers hope to identify targets that could lead to better therapies. The work focuses on how OSMR contributes to cancer progression and how it interacts with other cells in the tumor microenvironment.
Why it matters
Potential benefit: If successful, findings could reveal new targets for therapies that may slow progression or improve treatment responses for PDAC patients.
How similar studies have gone: Previous studies have linked OSM/OSMR signaling to cancer progression, with ongoing exploration of this pathway in PDAC.
Where this research is happening
-
Portland VA Medical Center
Portland, United States Active
Researchers
- Principal investigator: Zimmers, Teresa a — Portland VA Medical Center
- Study coordinator: Zimmers, Teresa a
Related research
Other NIH-funded projects on the same topics.
-
PASSCODE: Coordinating and Sharing PDAC stromal research data
A networked effort at NYU School of Medicine aims to study how the pancreatic cancer stroma shapes tumor growth and patient outcomes, by coordinating researchers, sharing data, and educating the field.
-
Total Neoadjuvant Therapy for Borderline or Locally Advanced Pancreatic Cancer
A multi-part treatment approach tests giving all chemotherapy and targeted radiotherapy before surgery to help patients with tough-to-remove pancreatic cancer become eligible for curative surgery.
-
Low-dose, motion-aware MRI to study pancreatic cancer
A new MRI method using low-dose contrast and motion-resolved imaging is being explored to better characterize pancreatic cancer in patients.
-
SOAT1 as a target in pancreatic cancer
Researchers are studying a specific enzyme, SOAT1, to see if blocking it can slow down or stop pancreatic cancer progression in models that mimic human disease.
-
Turning inflammatory scar cells in the pancreas into helpers to improve treatment response
This project will try to change inflammatory, scar-forming cells around pancreatic tumors so treatments and the immune system can work better for people with pancreatic ductal adenocarcinoma.
-
Blocking cancer's iron supply to help pancreatic cancer drugs work better
This project tests whether stopping pancreatic cancer cells from using stored iron can help people with KRAS-mutant pancreatic ductal adenocarcinoma respond longer to new KRAS-targeting drugs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.